Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Argus Health
Daiichi Sankyo
Fuji
Citi
McKesson
Chinese Patent Office
UBS
Baxter

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 061904

« Back to Dashboard

NDA 061904 describes ERYTHROMYCIN ETHYLSUCCINATE, which is a drug marketed by Ani Pharms Inc, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Arbor Pharms Llc, Barr, and Mylan, and is included in eleven NDAs. It is available from two suppliers. Additional details are available on the ERYTHROMYCIN ETHYLSUCCINATE profile page.

The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and two drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
Summary for 061904
Tradename:ERYTHROMYCIN ETHYLSUCCINATE
Applicant:Arbor Pharms Llc
Ingredient:erythromycin ethylsuccinate
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 061904
Ingredient-typeMacrolides
Physiological EffectDecreased Sebaceous Gland Activity
Suppliers and Packaging for NDA: 061904
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate TABLET;ORAL 061904 ANDA Arbor Pharmaceuticals, Inc. 24338-110 N 24338-110-13

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 400MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:BXRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Harvard Business School
Covington
Teva
Cantor Fitzgerald
Boehringer Ingelheim
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.